Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 190

1.

Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients.

McEvoy AC, Warburton L, Al-Ogaili Z, Celliers L, Calapre L, Pereira MR, Khattak MA, Meniawy TM, Millward M, Ziman M, Gray ES.

BMC Cancer. 2018 Jul 9;18(1):726. doi: 10.1186/s12885-018-4637-6.

2.

Medical Oncology Group of Australia position statement and membership survey on voluntary assisted dying.

Karapetis CS, Stein B, Koczwara B, Harrup R, Milleshkin L, Parente P, Millward M, Haines I, Blinman P, Olver I.

Intern Med J. 2018 Jul;48(7):774-779. doi: 10.1111/imj.13951.

PMID:
29984513
3.

Implementation of next generation sequencing technology for somatic mutation detection in routine laboratory practice.

Giardina T, Robinson C, Grieu-Iacopetta F, Millward M, Iacopetta B, Spagnolo D, Amanuel B.

Pathology. 2018 Jun;50(4):389-401. doi: 10.1016/j.pathol.2018.01.005. Epub 2018 May 8.

PMID:
29752127
4.

A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours.

Dredge K, Brennan TV, Hammond E, Lickliter JD, Lin L, Bampton D, Handley P, Lankesheer F, Morrish G, Yang Y, Brown MP, Millward M.

Br J Cancer. 2018 Apr;118(8):1035-1041. doi: 10.1038/s41416-018-0006-0. Epub 2018 Mar 13.

PMID:
29531325
5.

Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC.

McKeage MJ, Kotasek D, Markman B, Hidalgo M, Millward MJ, Jameson MB, Harris DL, Stagg RJ, Kapoun AM, Xu L, Hughes BGM.

Target Oncol. 2018 Feb;13(1):89-98. doi: 10.1007/s11523-017-0543-0.

PMID:
29188408
6.

Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma.

McEvoy AC, Calapre L, Pereira MR, Giardina T, Robinson C, Khattak MA, Meniawy TM, Pritchard AL, Hayward NK, Amanuel B, Millward M, Ziman M, Gray ES.

Oncotarget. 2017 Aug 18;8(45):78890-78900. doi: 10.18632/oncotarget.20354. eCollection 2017 Oct 3.

7.

Isolation and detection of circulating tumour cells from metastatic melanoma patients using a slanted spiral microfluidic device.

Aya-Bonilla CA, Marsavela G, Freeman JB, Lomma C, Frank MH, Khattak MA, Meniawy TM, Millward M, Warkiani ME, Gray ES, Ziman M.

Oncotarget. 2017 Jun 27;8(40):67355-67368. doi: 10.18632/oncotarget.18641. eCollection 2017 Sep 15.

8.

Treatment of ALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context.

Itchins M, Chia PL, Hayes SA, Howell VM, Gill AJ, Cooper WA, John T, Mitchell P, Millward M, Clarke SJ, Solomon B, Pavlakis N.

Asia Pac J Clin Oncol. 2017 Aug;13 Suppl 3:3-13. doi: 10.1111/ajco.12754. Review.

PMID:
28795492
9.

Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma.

Calapre L, Warburton L, Millward M, Ziman M, Gray ES.

Cancer Lett. 2017 Sep 28;404:62-69. doi: 10.1016/j.canlet.2017.06.030. Epub 2017 Jul 4. Review.

10.

Survey of practices around pharmaceutical company funding for continuing professional development among medical oncologists and trainees in Australia.

Lee YC, Kroon R, Koczwara B, Haines I, Francis K, Millward M, Kefford R, Olver I, Mileshkin L.

Intern Med J. 2017 Aug;47(8):888-893. doi: 10.1111/imj.13482.

PMID:
28485058
11.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ.

Ann Oncol. 2017 Jul 1;28(7):1631-1639. doi: 10.1093/annonc/mdx176.

12.

Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.

Bowyer S, Prithviraj P, Lorigan P, Larkin J, McArthur G, Atkinson V, Millward M, Khou M, Diem S, Ramanujam S, Kong B, Liniker E, Guminski A, Parente P, Andrews MC, Parakh S, Cebon J, Long GV, Carlino MS, Klein O.

Br J Cancer. 2017 Apr 11;116(8):e15. doi: 10.1038/bjc.2017.59. Epub 2017 Mar 21. No abstract available.

13.

Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity.

Lesterhuis WJ, Bosco A, Millward MJ, Small M, Nowak AK, Lake RA.

Nat Rev Drug Discov. 2017 Apr;16(4):264-272. doi: 10.1038/nrd.2016.233. Epub 2017 Jan 6. Review.

PMID:
28057932
14.

Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma.

Mesbah Ardakani N, Leslie C, Grieu-Iacopetta F, Lam WS, Budgeon C, Millward M, Amanuel B.

Pigment Cell Melanoma Res. 2017 Mar;30(2):233-242. doi: 10.1111/pcmr.12569. Epub 2017 Mar 7.

PMID:
28002643
15.

Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists.

Atkinson V, Long GV, Menzies AM, McArthur G, Carlino MS, Millward M, Roberts-Thomson R, Brady B, Kefford R, Haydon A, Cebon J.

Asia Pac J Clin Oncol. 2016 Dec;12 Suppl 7:5-12. doi: 10.1111/ajco.12656.

PMID:
27905182
16.

Cutaneous Metastatic Melanoma Resembling a Halo Nevus, in the Setting of PD-1 Inhibition.

Harvey NT, Millward M, Macgregor K, Bucat RP, Wood BA.

Am J Dermatopathol. 2016 Dec;38(12):e159-e162.

PMID:
27870733
17.

A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors.

Soria JC, Gan HK, Blagden SP, Plummer R, Arkenau HT, Ranson M, Evans TR, Zalcman G, Bahleda R, Hollebecque A, Lemech C, Dean E, Brown J, Gibson D, Peddareddigari V, Murray S, Nebot N, Mazumdar J, Swartz L, Auger KR, Fleming RA, Singh R, Millward M.

Ann Oncol. 2016 Dec;27(12):2268-2274. doi: 10.1093/annonc/mdw427. Epub 2016 Oct 11.

PMID:
27733373
18.

Sentinel node biopsy for melanoma: The medical oncology perspective.

Menzies AM, Atkinson VG, Brown MP, Carlino MS, Cebon J, Guminski A, Kefford RF, Long GV, McArthur G, McNeil CM, Millward M, Sandhu S.

Aust Fam Physician. 2015 Dec;44(12):875-6. No abstract available.

PMID:
27505912
19.

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.

Bowyer S, Prithviraj P, Lorigan P, Larkin J, McArthur G, Atkinson V, Millward M, Khou M, Diem S, Ramanujam S, Kong B, Liniker E, Guminski A, Parente P, Andrews MC, Parakh S, Cebon J, Long GV, Carlino MS, Klein O.

Br J Cancer. 2016 May 10;114(10):1084-9. doi: 10.1038/bjc.2016.107. Epub 2016 Apr 28.

20.

Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results.

Harrison SJ, Mainwaring P, Price T, Millward MJ, Padrik P, Underhill CR, Cannell PK, Reich SD, Trikha M, Spencer A.

Clin Cancer Res. 2016 Sep 15;22(18):4559-66. doi: 10.1158/1078-0432.CCR-15-2616. Epub 2016 Apr 26.

21.

PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors.

Meniawy TM, Lake RA, McDonnell AM, Millward MJ, Nowak AK.

Lung Cancer. 2016 Mar;93:9-16. doi: 10.1016/j.lungcan.2015.12.006. Epub 2015 Dec 30.

PMID:
26898608
22.

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.

Gray ES, Rizos H, Reid AL, Boyd SC, Pereira MR, Lo J, Tembe V, Freeman J, Lee JH, Scolyer RA, Siew K, Lomma C, Cooper A, Khattak MA, Meniawy TM, Long GV, Carlino MS, Millward M, Ziman M.

Oncotarget. 2015 Dec 8;6(39):42008-18. doi: 10.18632/oncotarget.5788.

23.

A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma.

Nowak AK, Cook AM, McDonnell AM, Millward MJ, Creaney J, Francis RJ, Hasani A, Segal A, Musk AW, Turlach BA, McCoy MJ, Robinson BW, Lake RA.

Ann Oncol. 2015 Dec;26(12):2483-90. doi: 10.1093/annonc/mdv387. Epub 2015 Sep 18.

PMID:
26386124
24.

A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial.

Davidson A, Veillard AS, Tognela A, Chan MM, Hughes BG, Boyer M, Briscoe K, Begbie S, Abdi E, Crombie C, Long J, Boyce A, Lewis CR, Varma S, Broad A, Muljadi N, Chinchen S, Espinoza D, Coskinas X, Pavlakis N, Millward M, Stockler MR; Australasian Lung cancer Trials Group (ALTG); Australasian Lung cancer Trials Group ALTG.

Ann Oncol. 2015 Nov;26(11):2280-6. doi: 10.1093/annonc/mdv373. Epub 2015 Sep 7.

PMID:
26347110
25.

Mutational Analysis of BRAF Inhibitor-Associated Squamoproliferative Lesions.

Clynick B, Tabone T, Fuller K, Erber W, Meehan K, Millward M, Wood BA, Harvey NT.

J Mol Diagn. 2015 Nov;17(6):644-51. doi: 10.1016/j.jmoldx.2015.05.009. Epub 2015 Aug 28.

PMID:
26319365
26.

FOXP3+ T regulatory lymphocytes in primary melanoma are associated with BRAF mutation but not with response to BRAF inhibitor.

Leslie C, Bowyer SE, White A, Grieu-Iacopetta F, Trevenen M, Iacopetta B, Amanuel B, Millward M.

Pathology. 2015 Oct;47(6):557-63. doi: 10.1097/PAT.0000000000000314.

PMID:
26308130
27.

Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT.

Francis RJ, Segard T, Morandeau L, Lee YC, Millward MJ, Segal A, Nowak AK.

Lung Cancer. 2015 Oct;90(1):55-60. doi: 10.1016/j.lungcan.2015.07.015. Epub 2015 Jul 30.

PMID:
26259878
28.

Bleeding Small Intestine Pyogenic Granuloma on 18F-FDG PET/CT.

Iravani A, Law A, Millward M, Warner M, Sparrow S.

Clin Nucl Med. 2015 Nov;40(11):869-70. doi: 10.1097/RLU.0000000000000929.

PMID:
26252336
29.

Patients' and doctors' preferences for adjuvant chemotherapy in resected non-small-cell lung cancer: What makes it worthwhile?

Blinman P, Hughes B, Crombie C, Christmas T, Hudson M, Veillard AS, Muljadi N, Millward M, Wright G, Flynn P, Windsor M, Stockler M, McLachlan SA; Australasian Lung Cancer Trials Group (ALTG).

Eur J Cancer. 2015 Aug;51(12):1529-37. doi: 10.1016/j.ejca.2015.05.022. Epub 2015 Jun 6.

PMID:
26059196
30.

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.

Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Swann S, Legos JJ, Jin F, Mookerjee B, Flaherty K.

Lancet. 2015 Aug 1;386(9992):444-51. doi: 10.1016/S0140-6736(15)60898-4. Epub 2015 May 31.

PMID:
26037941
31.

Secreted frizzled-related protein 4 inhibits glioma stem-like cells by reversing epithelial to mesenchymal transition, inducing apoptosis and decreasing cancer stem cell properties.

Bhuvanalakshmi G, Arfuso F, Millward M, Dharmarajan A, Warrier S.

PLoS One. 2015 Jun 1;10(6):e0127517. doi: 10.1371/journal.pone.0127517. eCollection 2015.

32.

Equivocal ALK fluorescence in-situ hybridization (FISH) cases may benefit from ancillary ALK FISH probe testing.

Selinger C, Cooper W, Lum T, McNeil C, Morey A, Waring P, Amanuel B, Millward M, Peverall J, Van Vliet C, Christie M, Tran Y, Diakos C, Pavlakis N, Gill AJ, O'Toole S.

Histopathology. 2015 Nov;67(5):654-63. doi: 10.1111/his.12708. Epub 2015 May 24.

PMID:
25847523
33.

The aggregation of early-onset melanoma in young Western Australian families.

Ward SV, Dowty JG, Webster RJ, Cadby G, Glasson EJ, Heyworth JS, Emery J, Cole JM, Millward MJ, Wood FM, Palmer LJ.

Cancer Epidemiol. 2015 Jun;39(3):346-52. doi: 10.1016/j.canep.2015.03.007. Epub 2015 Apr 3.

PMID:
25843692
34.

Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment.

Gray ES, Reid AL, Bowyer S, Calapre L, Siew K, Pearce R, Cowell L, Frank MH, Millward M, Ziman M.

J Invest Dermatol. 2015 Aug;135(8):2040-2048. doi: 10.1038/jid.2015.127. Epub 2015 Apr 1.

35.

Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma.

Schadendorf D, Amonkar MM, Stroyakovskiy D, Levchenko E, Gogas H, de Braud F, Grob JJ, Bondarenko I, Garbe C, Lebbe C, Larkin J, Chiarion-Sileni V, Millward M, Arance A, Mandalà M, Flaherty KT, Nathan P, Ribas A, Robert C, Casey M, DeMarini DJ, Irani JG, Aktan G, Long GV.

Eur J Cancer. 2015 May;51(7):833-40. doi: 10.1016/j.ejca.2015.03.004. Epub 2015 Mar 17.

PMID:
25794603
36.

PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples.

Winterhoff B, Freyer L, Hammond E, Giri S, Mondal S, Roy D, Teoman A, Mullany SA, Hoffmann R, von Bismarck A, Chien J, Block MS, Millward M, Bampton D, Dredge K, Shridhar V.

Eur J Cancer. 2015 May;51(7):879-892. doi: 10.1016/j.ejca.2015.02.007. Epub 2015 Mar 5.

37.

Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR.

Reid AL, Freeman JB, Millward M, Ziman M, Gray ES.

Clin Biochem. 2015 Oct;48(15):999-1002. doi: 10.1016/j.clinbiochem.2014.12.007. Epub 2014 Dec 16.

PMID:
25523300
38.

Testing for human papillomavirus in BRAF inhibitor-associated verrucous keratoses.

Clynick B, Tabone T, Heel K, Erber W, Wood BA, Millward M, Harvey NT.

J Cutan Pathol. 2015 Jan;42(1):73-5. doi: 10.1111/cup.12403. Epub 2014 Dec 8. No abstract available.

PMID:
25487366
39.

Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial.

Ellis PM, Shepherd FA, Millward M, Perrone F, Seymour L, Liu G, Sun S, Cho BC, Morabito A, Leighl NB, Stockler MR, Lee CW, Wierzbicki R, Cohen V, Blais N, Sangha RS, Favaretto AG, Kang JH, Tsao MS, Wilson CF, Goldberg Z, Ding K, Goss GD, Bradbury PA; NCIC CTG; Australasian Lung Cancer Trials Group; NCI Naples Clinical Trials Unit.

Lancet Oncol. 2014 Nov;15(12):1379-88. doi: 10.1016/S1470-2045(14)70472-3. Epub 2014 Oct 15.

PMID:
25439692
40.

The effects of phenoxodiol on the cell cycle of prostate cancer cell lines.

Mahoney S, Arfuso F, Millward M, Dharmarajan A.

Cancer Cell Int. 2014 Nov 8;14(1):110. doi: 10.1186/s12935-014-0110-z. eCollection 2014.

41.

BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer.

Falchook GS, Millward M, Hong D, Naing A, Piha-Paul S, Waguespack SG, Cabanillas ME, Sherman SI, Ma B, Curtis M, Goodman V, Kurzrock R.

Thyroid. 2015 Jan;25(1):71-7. doi: 10.1089/thy.2014.0123.

42.

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Casey M, Ouellet D, Martin AM, Le N, Patel K, Flaherty K.

N Engl J Med. 2014 Nov 13;371(20):1877-88. doi: 10.1056/NEJMoa1406037. Epub 2014 Sep 29.

43.

Cancer stem-like cells from head and neck cancers are chemosensitized by the Wnt antagonist, sFRP4, by inducing apoptosis, decreasing stemness, drug resistance and epithelial to mesenchymal transition.

Warrier S, Bhuvanalakshmi G, Arfuso F, Rajan G, Millward M, Dharmarajan A.

Cancer Gene Ther. 2014 Sep;21(9):381-8. doi: 10.1038/cgt.2014.42. Epub 2014 Aug 8.

PMID:
25104726
44.

Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436).

Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau HT, Brown MP, Hamid O, Infante JR, Millward M, Pavlick A, Chin MT, O'Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF.

Clin Cancer Res. 2014 Sep 1;20(17):4449-58. doi: 10.1158/1078-0432.CCR-14-0887. Epub 2014 Jun 23.

45.

Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma.

Bowyer SE, Rao AD, Lyle M, Sandhu S, Long GV, McArthur GA, Raleigh JM, Hicks RJ, Millward M.

Melanoma Res. 2014 Oct;24(5):504-8. doi: 10.1097/CMR.0000000000000099.

PMID:
24933606
46.

Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma.

Klinac D, Gray ES, Freeman JB, Reid A, Bowyer S, Millward M, Ziman M.

BMC Cancer. 2014 Jun 11;14:423. doi: 10.1186/1471-2407-14-423.

47.

Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine.

Grob JJ, Amonkar MM, Martin-Algarra S, Demidov LV, Goodman V, Grotzinger K, Haney P, Kämpgen E, Karaszewska B, Mauch C, Miller WH Jr, Millward M, Mirakhur B, Rutkowski P, Chiarion-Sileni V, Swann S, Hauschild A.

Ann Oncol. 2014 Jul;25(7):1428-36. doi: 10.1093/annonc/mdu154. Epub 2014 Apr 25.

PMID:
24769640
48.

Positive sentinel lymph node metastasis from a metastasis in Melanoma.

Bowyer S, Feeney K, Millward M.

Asia Pac J Clin Oncol. 2014 Dec;10(4):376-7. doi: 10.1111/ajco.12169. Epub 2014 Jan 24.

PMID:
24456240
49.

Wnt antagonist, secreted frizzled-related protein 4 (sFRP4), increases chemotherapeutic response of glioma stem-like cells.

Warrier S, Balu SK, Kumar AP, Millward M, Dharmarajan A.

Oncol Res. 2013;21(2):93-102. doi: 10.3727/096504013X13786659070154.

PMID:
24406045
50.

The association of host and genetic melanoma risk factors with Breslow thickness in the Western Australian Melanoma Health Study.

Cadby G, Ward SV, Cole JM, Moses EK, Millward M, Palmer LJ.

Br J Dermatol. 2014 Apr;170(4):851-7. doi: 10.1111/bjd.12829.

PMID:
24405011

Supplemental Content

Loading ...
Support Center